OFFICE OF THE DIRECTOR
Kate Brown, Governor

Oregon Health Authority

500 Summer St NE E20
Salem OR 97301
Voice: 503-947-2340
Fax: 503-947-2341
www.Oregon.Gov/OHA
www.health.oregon.gov

OFFICIAL WEBSITE NOTICE
**Posting Date: December 14, 2016**

# RECOMMENDATIONS OF DRUG USE REVIEW / PHARMACY AND THERAPEUTICS COMMITTEE

The Oregon Drug Use Review / Pharmacy and Therapeutics Committee met in Salem, Oregon on Thursday, November 17, 2016. The Committee considered in order of priority: the safety and efficacy of the drugs being considered, the ability of Oregonians to access effective prescription drugs that are appropriate for their clinical conditions and finally, substantial differences in costs of drugs within the same therapeutic class. Based upon the clinical information presented by staff [i] and all public comment offered,[ii] while considering the impact on special populations, the Committee makes the following recommendations for the Oregon Practitioner-Managed Prescription Drug Plan (PMPDP) or for any other preferred drug list established by the Oregon Health Authority:

## Drug Use Review Recommendations:

Dose Consolidation Proposal
The Committee recommended implementing the dose consolidation proposal.

Synagis® (palivizumab) Drug Policy
The Committee recommended updating the current clinical prior authorization (PA) criteria to require that the patient's parent/caregiver and prescriber comply with all case management services, including obtaining current patient weight throughout the approved treatment period.

Procysbi® (cysteamine bitartrate) Drug Policy
The Committee agreed that no further research is needed at this time and recommended maintaining the current PA policy as presented.

H.P. Acthar® Gel (repository corticotropin injection) Drug Policy

The Committee agreed that no further research is needed at this time and recommended maintaining the current PA policy as presented.

**Practitioner-Managed Prescription Drug Plan (PMPDP) Recommendations:**

Oral Cystic Fibrosis Modulators Class Update

The Committee agreed that no further research is needed at this time and recommended no changes to the PMPDP based on the clinical evidence. The Committee recommended continuation of current clinical PA criteria approval in appropriate patients and to amend the proposed criteria to require Medical Director approval for Orkambi® (lumacaftor/ivacaftor) in children ages 6 through 11 years of age.

Opioid Analgesics Class Update

The Committee recommended maintaining Troxyca® ER (oxycodone and naltrexone) extended-release capsules as non-preferred on the PMPDP based on clinical evidence and to adopt the proposed clinical PA criteria for short-acting and long-acting opioid analgesics including:

- exempting patients with a terminal diagnosis or cancer diagnosis from the proposed clinical PA criteria;
- requiring PA for all non-preferred short-acting opioids and preferred short-acting opioids prescribed for more than 7 days;
- requiring PA for all long-acting opioid analgesics;
- updating quantity limits for newly approved long-acting opioids

The Committee recommended modifying question #8 of the proposed short-acting opioid PA criteria to remove the restriction that opioid analgesics be prescribed by a single prescriber or prescribing practice and instead request prescribers verify, using the PDMP at least once in the last three months, what scheduled substances their patients have been recently prescribed. For the long-acting opioid PA criteria, the Committee recommended making visual changes to Table 1 to highlight methadone, when used for pain, as being a uniquely more dangerous opioid than the other agents. After comparative cost consideration in executive session the Committee recommended no changes to the PMPDP.

Multiple Sclerosis Drug Class Update

The Committee recommended no changes to the PMPDP based on evidence from the DERP report and to adopt the proposed revision to the clinical PA criteria to require assessment of lymphocyte counts before initiating therapy with Tecfidera®(dimethyl fumarate). The Committee recommended modifying question #9 to request confirmation of a negative pregnancy test prior to initiation of Aubagio® (teriflunomide). After comparative cost consideration in executive session the Committee recommended making Glatopa™ (glatiramer acetate) non-preferred on the PMPDP and to request pharmacies instead dispense brand name Copaxone® (glatiramer acetate).

| DRUG | CHANGE |
|---|---|
| Glatopa™ (glatiramer acetate) | Make non-preferred on the PMPDP |

Taltz® (ixekizumab) New Drug Evaluation

The Committee recommended incorporating Taltz® (ixekizumab) into the current PA criteria for Biologics, but no other changes to the clinical criteria. After comparative cost consideration in executive session the Committee recommended maintaining Taltz® (ixekizumab) as non-preferred and no other changes to the PMPDP.

Non-statin Lipid-lowering Agents Class Update

The Committee recommended no changes to the PMPDP based on updated evidence and to revise current clinical PA criteria for omega-3 fatty acids to remove requirement of failure or contraindication to niacin therapy as condition for approval. The Committee also proposed modifying the goal for the omega-3 fatty acids PA to state it is to restrict use of omega-3 fatty acids to patients at increased risk for pancreatitis. The Committee recommended no changes to clinical PA criteria for PCSK9 Inhibitors, mipomersen or lomitapide and after comparative cost consideration in executive session, recommended making no changes to the PMPDP.

The Committee has made these recommendations to the Oregon Health Authority for approval by the Director of the Oregon Health Authority.

## APPROVAL BY THE DIRECTOR OF THE OREGON HEALTH AUTHORITY

The recommendations of the Drug Use Review / Pharmacy and Therapeutics Committee are approved. Recommendations with respect to the inclusion of a drug on the Practitioner-Managed Prescription Drug Plan will be put into place no earlier than 60 days from the date this notice is posted on the web site.

Lynne Saxton
Director

12-14-16
Approval date

A request for reconsideration of this decision to adopt the recommendations of the Drug Use Review / Pharmacy and Therapeutics Committee must be filed with and received by the Director no later than 30 calendar days from the date of this notice. 2011 OR law, CH 730 (HB2100) Section 4

---

[i] http://www.orpdl.org/durm/meetings/meetingdocs/2016_11_17/finals/2016_11_17_PnT_Complete.pdf
[ii] http://www.orpdl.org/durm/meetings/meetingdocs/2016_11_17/finals/2016_11_17_WrittenTestimony.pdf